Gemspring Capital Announces Sale of Valant
Founded in 2005 and backed by Gemspring since 2019, Valant provides a comprehensive and differentiated software platform that enables customers to manage key operational, clinical, and financial workflows to drive optimal business and patient outcomes. Through its intuitive user experience and robust product suite – purpose-built for the behavioral health market – Valant has scaled to serve more than 22,000 behavioral health professionals across all 50 states.
During Gemspring's ownership, Valant developed and implemented an entirely new and modern technology platform, launched multiple new products, and made significant investments in management and operational infrastructure to extend its market leadership and drive meaningful growth.
"As we've scaled our business to meet the needs of behavioral health providers across the country, Gemspring has been a tremendous partner to Valant and has helped us drive product innovation and develop our go-to-market strategy," shared Valant CEO
"It's been incredibly rewarding to support Ram and the entire Valant team during this chapter of exceptional growth," said
Aeris Partners served as financial advisor and McDermott Will & Emery LLP served as legal counsel to Valant and Gemspring.
About Valant Medical Solutions
Valant is a software-as-a-service organization serving the needs of the behavioral healthcare industry. Valant's disruptive technology solutions combine deep domain and technical expertise to improve behavioral healthcare quality by reinventing how electronic healthcare record (EHR) systems serve mental health providers and their patients. Valant is headquartered in
About Gemspring Capital
Gemspring Capital, a
Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/gemspring-capital-announces-sale-of-valant-302004011.html
SOURCE Gemspring Capital
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle Announces $10 Million Partnership with the Nashville Symphony
- Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
- PMET Signs Letter of Intent with Matagami for Spodumene Concentrate Transshipment to the Rail Network
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share